PARP1 and neoplasm: While normal cells repair DSBs through HRR, cancer cells are unable to do so.[8, 9] As a result, PARP‐1 inhibitors block the repair of single‐strand breaks (SSBs), causing these breaks to evolve into DSBs during DNA replication, leading to the death of tumor cells while sparing normal cells.